INFECTIOUS DISEASE DIAGNOSTICS MARKET ANALYSIS

Infectious Disease Diagnostics Market, By Technique ( ELISA, Polymerase Chain Reaction (PCR),Immunoassays, Cell Cultures, Others),By Disease Indication (CNS Infection ,Meningitis, Brain Abscess), Diarrheal Disease ( Shigellosis, Cholera, Enteric/Typhoid Fever),Respiratory Infections(Tuberculosis, Influenza, Bronchitis),Blood Infections(Malaria, Dengue, Infectious Mononucleosis, Others),STDs(Chlamydia, Aids, Syphills, Others)),By End User (Hospitals, Diagnostic Centers, Clinics, Government Organizations), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

July 2022, Hoffmann-La Roche Ltd launched a new dual antigen and antibody diagnostic test for hepatitis C. The new Elecsys HCV Duo is one the first commercially available immunoassay test that allows the simultaneous and independent determination of the hepatitis C virus strain from a single human plasma or serum sample.
In December 2021, Roche announced the launch of the first infectious disease tests on the Cobas 5800 system, a new molecular laboratory instrument, in countries accepting the CE mark.